Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Torii Pharmaceutical Co., Ltd.    4551   JP3635800000

TORII PHARMACEUTICAL CO., LTD.

(4551)
  Report
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Torii Pharmaceutical : Signs Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
01/16/2020 | 08:19am EDT

Torii Pharmaceutical Co., Ltd. (Torii) (TSE: 4551) has announced today that Torii has signed an exclusive license agreement with Japan Tobacco Inc. (JT) (TSE: 2914) for co-development and commercialization of tapinarof, a topical, therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in Japan.

JT signed an exclusive license agreement on January 15, 2020, with Dermavant Sciences GmbH (Dermavant) for the development and commercialization of tapinarof for dermatological diseases and conditions in Japan.

Under the terms of the agreement, Torii and JT will jointly develop tapinarof in Japan, with Torii commercializing it once the development and necessary approval procedures have been completed. Torii will pay upfront licensing fees to JT.

The effects on business performance of the agreement are expected to be minor in this fiscal year, and will be included in Torii's forecasts for the fiscal year 2020 to be announced on February 6, 2020.

Torii will undertake efforts to enhance the commercial value of tapinarof in Japan by leveraging Torii's significant experience in the dermatology area.

ABOUT Tapinarof

Tapinarof is a potential first-in-class topical TAMA in Japan, which Dermavant is developing for the treatment of psoriasis and atopic dermatitis. The Phase 3 clinical studies for tapinarof in patients with plaque psoriasis are currently being conducted in the U.S. by Dermavant.

Contact:

Tel: +81-3-3231-6814

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
JAPAN TOBACCO INC. 1.10% 1926 End-of-day quote.-0.98%
TORII PHARMACEUTICAL CO., LTD. 3.71% 2348 End-of-day quote.-1.14%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TORII PHARMACEUTICAL CO.,
02/07TORII PHARMACEUTICAL : Progress of the Medium-Term Management Plan 2021 and Revi..
AQ
01/24JAPAN TOBACCO : JT Receives Manufacturing and Marketing Approval of CORECTIM Oin..
AQ
01/16TORII PHARMACEUTICAL : Signs Exclusive License Agreement with JT for Development..
AQ
2019TORII PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2019JAPAN TOBACCO : JT Files New Drug Application of Enarodustat, for the Treatment ..
AQ
2019TORII PHARMACEUTICAL : Transfer of rights to uricosuric agent URINORM
AQ
2019JAPAN TOBACCO INC. : - Top-line Results of Phase 3 Clinical Studies of JTZ-951, ..
AQ
2019TORII PHARMACEUTICAL CO., LTD. : Ex-dividend day for interim dividend
FA
2019TORII PHARMACEUTICAL : Results of Voluntary Retirement Program
AQ
2019JAPAN TOBACCO : Torii Pharmaceutical Co., Ltd. - Top-line Results of JTE-052 Oin..
AQ
More news
Financials (JPY)
Sales 2019 42 200 M
EBIT 2019 700 M
Net income 2019 26 000 M
Debt 2019 -
Yield 2019 1,83%
P/E ratio 2019 2,82x
P/E ratio 2020 35,1x
Capi. / Sales2019 1,74x
Capi. / Sales2020 1,88x
Capitalization 73 376 M
Chart TORII PHARMACEUTICAL CO.,
Duration : Period :
Torii Pharmaceutical Co.,  Technical Analysis Chart | 4551 | JP3635800000 | MarketScreener
Technical analysis trends TORII PHARMACEUTICAL CO.,
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 2 616,00  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Goichi Matsuda President, CEO & Representative Director
Megumi Kajiwara Manager-Information Systems
Yuko Kariya Director & Manager-Reliability Assurance Group
Katsunobu Fujiwara Director & Manager-Sales Planning
Masao Torikai Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
TORII PHARMACEUTICAL CO., LTD.-1.14%679
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
NOVARTIS-16.30%180 007
PFIZER, INC.-21.13%171 422